Abstract
Clinical trials studying neoadjuvant and adjuvant therapy around prostatectomy for patients with high‐risk prostate cancer have faced multiple challenges. Patients who have a very good response to neoadjuvant therapy may not wish to continue to adjuvant treatment, and prostate‐specific antigen–based end points are difficult to interpret because of variations in testosterone recovery.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
